01:40:03 Europe / Stockholm

Kalender

2024-10-31 Kvartalsrapport 2024-Q3
2024-08-29 Kvartalsrapport 2024-Q2
2024-04-30 X-dag ordinarie utdelning GENT 0.00 NOK
2024-04-30 Kvartalsrapport 2024-Q1
2024-04-29 Årsstämma 2024
2024-02-09 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-05 Kvartalsrapport 2023-Q1
2023-05-05 X-dag ordinarie utdelning GENT 0.00 NOK
2023-05-04 Årsstämma 2023
2023-02-16 Bokslutskommuniké 2022
2022-10-27 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-19 X-dag ordinarie utdelning GENT 0.00 NOK
2022-05-18 Årsstämma 2022
2022-04-28 Kvartalsrapport 2022-Q1
2022-02-17 Bokslutskommuniké 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-05 X-dag ordinarie utdelning GENT 0.00 NOK
2021-05-04 Årsstämma 2021
2021-04-16 Kvartalsrapport 2021-Q1
2021-02-11 Bokslutskommuniké 2020
2020-10-29 Kvartalsrapport 2020-Q3
2020-08-21 Kvartalsrapport 2020-Q2
2020-05-15 X-dag ordinarie utdelning GENT 0.00 NOK
2020-05-14 Årsstämma 2020
2020-04-24 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-21 Extra Bolagsstämma 2019
2019-05-10 X-dag ordinarie utdelning GENT 0.00 NOK
2018-07-13 Extra Bolagsstämma 2018
2018-06-13 X-dag ordinarie utdelning GENT 0.00 NOK
2018-02-27 Bokslutskommuniké 2017
2017-06-06 Årsstämma 2017

Beskrivning

LandNorge
ListaOB Match
SektorHälsovård
IndustriBioteknik
Gentian Diagnostics är ett medicinskt diagnostikbolag som utvecklar och tillverkar in vitro diagnostiska reagenser för högkapacitetsanalysatorer. Gentians expertis och fokus ligger inom homogena immunanalyser, speciellt infektioner, inflammationer, njursvikt och kongestiv hjärtsvikt. Bolagets huvudkontor och produktionsanläggningar finns i Moss, Norge, och betjänar den globala human- och veterinärdiagnostikmarknaden genom försäljnings- och representationskontor i nyckelländer.
Filter arrow-icon
År arrow-icon
Typ arrow-icon
Språk arrow-icon
2024-05-02 14:09:26 Gentian Diagnostics: Mandatory notificaton of trade
2024-04-30 08:00:00 Gentian Diagnostics: First quarter 2024 report
2024-04-29 13:33:51 Gentian Diagnostics: Minutes from Annual General Meeting
2024-03-21 09:15:00 Gentian Diagnostics: Notice of annual general meeting
2024-03-21 09:15:00 Gentian Diagnostics: CEO resignation
2024-03-21 08:30:00 Gentian Diagnostics: Annual report 2023
2024-02-09 08:00:00 GENT: Fourth quarter and full year 2023 report
2024-01-30 14:04:07 GENT: Invitation to presentation of fourth quarter results
2023-12-19 14:13:36 GENT: Disclosure of shareholding
2023-12-18 09:23:37 GENT: Resignation of board member
2023-12-11 13:29:01 GENT: Financial calendar
2023-11-24 10:07:59 GENT: Mandatory notification of trade
2023-10-26 08:00:00 GENT: Third quarter 2023 report
2023-10-18 12:19:14 GENT: Invitation to presentation of third quarter results
2023-08-29 13:55:29 GENT: Mandatory notification of trade
2023-08-24 08:00:00 GENT: Second quarter 2023 report
2023-08-16 09:34:48 GENT: Invitation to presentation of second quarter results
2023-06-15 08:38:12 GENT: Gentian acquires Getica for SEK 3.0 million
2023-05-10 10:42:30 GENT: Capital Markets Day at 12.30 CEST today
2023-05-08 14:41:19 Reminder: Invitation to Capital Markets Day 10 May 2023
2023-05-05 17:25:36 Disclosure of shareholdings - Holta Invest AS
2023-05-05 17:05:46 GENT: Mandatory notification of trade
2023-05-05 07:30:00 GENT: First quarter 2023 report
2023-05-04 11:18:21 GENT: Minutes from Annual General Meeting
2023-04-27 10:55:58 GENT: Invitation to presentation of first quarter results
2023-04-14 09:24:39 GENT: Gentian Diagnostics invites to Capital Markets Day
2023-04-12 13:12:08 GENT: Notice of annual general meeting
2023-03-30 16:48:43 GENT: Annual report 2022
2023-03-17 15:45:15 GENT: Financial calendar
2023-02-16 08:00:00 GENT: Fourth quarter and full year 2022 report
2023-02-10 13:42:57 GENT: Invitation to presentation of fourth quarter results
2022-12-15 12:50:41 GENT: Mandatory notification of trade
2022-12-14 15:24:42 GENT: Gentian Diagnostics appoints new CSO
2022-12-13 10:03:29 GENT: Financial calendar
2022-12-05 11:09:10 GENT: Patent granted for NT-proBNP in the U.S.
2022-10-27 08:15:23 GENT: Third quarter 2022 report
2022-10-27 08:00:00 GENT: Third quarter 2023 report